WORCESTER, Mass.--(BUSINESS WIRE)--Agilux Laboratories, Inc. a leading provider of DMPK discovery and development services, is pleased to announce that it is now offering MDCK/MDCK-MDR1 assays, in addition to the existing Caco-2 assays, for assessing the membrane permeability properties of early drug discovery compounds. These permeability assays are part of their extensive suite of ADMET in vitro assay services. Caco-2 assays are used to predict intestinal absorption and also potential efflux by transporters, including P-glycoprotein (Pgp). Likewise, MDCK cells transfected with human MDR1 (Pgp) are useful for assessing candidate compounds for potential as a Pgp substrate or inhibitor, as well as blood-brain-barrier penetration. These assays have been extensively evaluated and qualified to assure their optimum performance and reliability.
